Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 7, 2025
Data Byte
MS market dynamics: Ocrevus still king as Kesimpta sales boom
Plus: Briumvi shows signs of growth, while sales of oral therapies remain mostly flat
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Dec 17, 2024
Deals
Candid strikes trio of T cell engager partnerships for autoimmunity
BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals
BioCentury | Dec 13, 2024
Product Development
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan
How CEOs are managing through uncertainty, and why ‘boring’ naked mAbs are the smart move in one field
BioCentury | Nov 27, 2024
Data Byte
MS market: Ocrevus continues to grow as Kesimpta becomes multi-blockbuster
Orals faring worse than IV and subcutaneous products
BioCentury | Nov 26, 2024
Deals
Roche rewards Poseida’s shareholders with high premium in $1B takeout
If fulfilled, CVR tied to pipeline programs would drive deal’s value even further
Items per page:
1 - 10 of 1514